Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping.

Clinical pharmacology and therapeutics - 1 Dec 2002

Lee Jang-Ik, Chaves-Gnecco Diego, Amico Janet A, Kroboth Patricia D, Wilson John W, Frye Reginald F

Abstract excerpt

OBJECTIVES: Determination of hepatic and intestinal cytochrome P450 (CYP) 3A activity is important, because CYP3A substrates show substantial variability in plasma concentrations as a result of variations in both hepatic and intestinal metabolism. The goals of this study were (1) to determine whether the hepatic and intestinal extraction ratios (ER(H) and ER(G), respectively) of the CYP3A probe drug midazolam are...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-Anxiety Agents
Share to Biological Availability

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cross-Over Studies

Share to Drug Administration Schedule

Share to Gas Chromatography-Mass Spectrometry

Share to Infusions, Intravenous

Share to Midazolam

Share to Oxidoreductases, N-Demethylating

Source

Identifiers

PMID: 12496753
DOI: 10.1067/mcp.2002.129068

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping.PMID 12496753Read ↗

A Population Pharmacokinetic Approach to Understand the Effect of Efavirenz on CYP3A Activity in Healthy Volunteers Using Midazolam as a Probe.Semantic proximity Read ↗

Application of Microdosed Intravenous Omeprazole to Determine Hepatic CYP2C19 Activity.Semantic proximity Read ↗

Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype.Semantic proximity Read ↗

Limited sampling strategy to predict AUC of the CYP3A phenotyping probe midazolam in adults: application to various assay techniques.Semantic proximity Read ↗

Physiologically based pharmacokinetic modeling to predict exposures in healthy Japanese subjects with different CYP2C19 phenotypes: Esomeprazole case study .Semantic proximity Read ↗

Evaluation of partial area under the concentration time curve to estimate midazolam apparent oral clearance for cytochrome P450 3A phenotyping.Semantic proximity Read ↗

A nanogram dose of the CYP3A probe substrate midazolam to evaluate drug interactions.Semantic proximity Read ↗

In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration.Semantic proximity Read ↗

Evaluation of limited sampling models for prediction of oral midazolam AUC for CYP3A phenotyping and drug interaction studies.Semantic proximity Read ↗

Microsomal prediction of in vivo clearance and associated interindividual variability of six benzodiazepines in humans.Semantic proximity Read ↗

Inhibitory effect of ketoconazole on the pharmacokinetics of a multireceptor tyrosine kinase inhibitor BMS-690514 in healthy participants: assessing the mechanism of the interaction with physiologically-based pharmacokinetic simulations.Semantic proximity Read ↗

Investigation of the in vivo activity of CYP3A in Brazilian volunteers: comparison of midazolam and omeprazole as drug markers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.